Clinical DevelopmentLast reviewed May 2026

Bridging Study(Bridging Study)

A clinical study conducted to allow extrapolation of efficacy and safety data from one region or population to another.

Usage Examples

The bridging study compared Japanese PK profiles to the US pivotal trial population prior to PMDA filing.
FDA accepted the EU pivotal Phase 3 data supported by a 100-patient US bridging study.

What is Bridging Study?

Bridging studies establish that clinical data generated in one ethnic, regional, or demographic population can be applied to another — most commonly supporting registration in a new region based on prior global clinical data. ICH E5 provides the framework: bridging studies address whether ethnic, environmental, or cultural factors could meaningfully alter drug behavior, and they generate the data needed to justify extrapolation.

In practice, bridging studies are frequently used to support Japanese or Asian regional approval based on US/EU pivotal data, or to support US approval based on ex-US pivotal data. The bridging package typically includes PK comparison across populations, selected clinical evidence in the target population, and scientific justification that no region-specific differences affect efficacy or safety conclusions. FDA's use of foreign data guidance (2024) expanded acceptance of ex-US pivotal data with appropriate bridging.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E5, ICH E17, FDA FOREIGN DATA GUIDANCE.

FDAEMAPMDA

When This Matters

The bridging study compared Japanese PK profiles to the US pivotal trial population prior to PMDA filing.
FDA accepted the EU pivotal Phase 3 data supported by a 100-patient US bridging study.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E5ICH E17FDA FOREIGN DATA GUIDANCE

Frequently Asked Questions

When pivotal clinical data comes from a population different from the target approval region and ethnic, environmental, or practice-pattern differences could plausibly affect safety or efficacy. ICH E5 provides decision framework; regulator consultation via pre-submission meetings is standard.

Bioequivalence demonstrates equivalence between products (typically generic vs. reference). Bridging demonstrates transferability of clinical conclusions across populations or regions. Different purposes; different study designs.

Increasingly yes for PK bridging — population PK modeling combined with physiologically-based PK (PBPK) can support cross-region extrapolation without new clinical PK studies. Clinical bridging for efficacy remains harder to replace modeling-only.